Literature DB >> 17142982

Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers.

Mutsuko Honda1, Hiromichi Itoh, Tadakiyo Suzuki, Yukiya Hashimoto.   

Abstract

The population pharmacokinetic parameters of mizoribine in healthy subjects were estimated using a nonlinear mixed effects model (NONMEM) program. Pharmacokinetic data for population analysis were obtained in the previous study, in which 24 healthy Caucasian male subjects participated in a single-dose (3, 6, 9, 12 mg/kg) study, and 12 subjects participated in a multiple-dose (6, 12 mg/kg/d) study. The mean value of the absorption lag time, absorption rate constant (KA), and apparent distribution volume (V/F) was estimated to be 0.349 h, 0.869 h-1, and 0.834 l/kg, respectively. Oral clearance (CL/F) was modeled with creatinine clearance (CLcr), and the mean value was estimated to be 1.93.CLcr l/h. In addition, pharmacokinetic parameters in individual 36 subjects were obtained from population estimates according to Bayes' theorem. Pharmacokinetic parameters (KA, V/F, and CL/F) in the single-dose study were almost constant at a dose range of 3-12 mg/kg, and were similar to those in the multiple-dose study. These findings indicated that the pharmacokinetics of mizoribine is well described by a simple one-compartment model with first-order absorption.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142982     DOI: 10.1248/bpb.29.2460

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

1.  Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation.

Authors:  Kazuya Ishida; Osamu Motoyama; Seiichiro Shishido; Kazuo Tsuzuki; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2012-02-25       Impact factor: 2.801

2.  Population pharmacokinetics of mizoribine in adult recipients of renal transplantation.

Authors:  Kazuya Ishida; Masahiko Okamoto; Michio Ishibashi; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2011-07-14       Impact factor: 2.801

3.  The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.

Authors:  Takuhito Nagai; Osamu Uemura; Hisashi Kaneda; Katsumi Ushijima; Kazuhide Ohta; Yoshimitsu Gotoh; Kenichi Satomura; Masaki Shimizu; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2016-11-21       Impact factor: 2.801

Review 4.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

5.  Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.

Authors:  Hisashi Kaneda; Masaki Shimizu; Kazuhide Ohta; Katsumi Ushijima; Yoshimitsu Gotoh; Kenichi Satomura; Takuhito Nagai; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Mari Takaai; Yukiya Hashimoto; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2015-12-09       Impact factor: 2.801

6.  Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges.

Authors:  Joseph R Inigo; Rahul Kumar; Dhyan Chandra
Journal:  Trends Cancer       Date:  2021-09-24

7.  Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.

Authors:  Takao Saito; Masayuki Iwano; Koichi Matsumoto; Tetsuya Mitarai; Hitoshi Yokoyama; Noriaki Yorioka; Shinichi Nishi; Ashio Yoshimura; Hiroshi Sato; Satoru Ogahara; Yoshie Sasatomi; Yasufumi Kataoka; Shiro Ueda; Akio Koyama; Shoichi Maruyama; Masaomi Nangaku; Enyu Imai; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

Review 8.  Toward Developing Chemical Modulators of Hsp60 as Potential Therapeutics.

Authors:  Qianli Meng; Bingbing X Li; Xiangshu Xiao
Journal:  Front Mol Biosci       Date:  2018-04-20

Review 9.  The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer.

Authors:  Abdullah Hoter; Sandra Rizk; Hassan Y Naim
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

10.  Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Authors:  Teruo Murakami; Nobuhiro Mori
Journal:  Pharmaceuticals (Basel)       Date:  2012-08-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.